EA200301299A1 - Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс - Google Patents

Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс

Info

Publication number
EA200301299A1
EA200301299A1 EA200301299A EA200301299A EA200301299A1 EA 200301299 A1 EA200301299 A1 EA 200301299A1 EA 200301299 A EA200301299 A EA 200301299A EA 200301299 A EA200301299 A EA 200301299A EA 200301299 A1 EA200301299 A1 EA 200301299A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
prevention
treatment
cns damage
damage
Prior art date
Application number
EA200301299A
Other languages
English (en)
Other versions
EA006744B1 (ru
Inventor
Эстер Шохами
Original Assignee
Арес Трейдинг С. А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арес Трейдинг С. А. filed Critical Арес Трейдинг С. А.
Publication of EA200301299A1 publication Critical patent/EA200301299A1/ru
Publication of EA006744B1 publication Critical patent/EA006744B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение относится к применению ингибиторов IL-18 в получении лекарственного препарата для лечения и/или предотвращения повреждения центральной нервной системы, в особенности травматического повреждения головы.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200301299A 2001-05-25 2002-05-23 Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс EA006744B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112067 2001-05-25
PCT/EP2002/005666 WO2002096456A1 (en) 2001-05-25 2002-05-23 Use of il-18 inhibitors for treating or preventing cns injuries

Publications (2)

Publication Number Publication Date
EA200301299A1 true EA200301299A1 (ru) 2004-04-29
EA006744B1 EA006744B1 (ru) 2006-04-28

Family

ID=8177454

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301299A EA006744B1 (ru) 2001-05-25 2002-05-23 Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс

Country Status (30)

Country Link
US (1) US7655616B2 (ru)
EP (1) EP1390070B1 (ru)
JP (1) JP4344142B2 (ru)
KR (1) KR20040030625A (ru)
CN (1) CN1305529C (ru)
AU (1) AU2002314103B2 (ru)
BG (1) BG66395B1 (ru)
BR (1) BR0210007A (ru)
CA (1) CA2445664C (ru)
CY (1) CY1119190T1 (ru)
CZ (1) CZ307321B6 (ru)
DK (1) DK1390070T3 (ru)
EA (1) EA006744B1 (ru)
EE (1) EE05263B1 (ru)
ES (1) ES2617084T3 (ru)
HK (1) HK1069762A1 (ru)
HR (1) HRP20030842B1 (ru)
HU (1) HU230294B1 (ru)
IL (2) IL159014A0 (ru)
LT (1) LT1390070T (ru)
ME (1) ME00550B (ru)
MX (1) MXPA03010743A (ru)
NO (1) NO331882B1 (ru)
PL (1) PL216228B1 (ru)
PT (1) PT1390070T (ru)
RS (1) RS56006B1 (ru)
SK (1) SK288413B6 (ru)
UA (1) UA80396C2 (ru)
WO (1) WO2002096456A1 (ru)
ZA (1) ZA200308172B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1622939T1 (sl) 2003-05-13 2012-06-29 Merck Serono Sa Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
NZ552908A (en) * 2004-06-30 2009-11-27 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use thereof
US8128920B2 (en) * 2005-06-03 2012-03-06 Merck Serono Sa Use of IL-18BP isoforms for the treatment and/or prevention of neurological inflammatory diseases
WO2006128908A1 (en) 2005-06-03 2006-12-07 Ares Trading S.A. Production of recombinant il-18 binding protein
EP1891088B1 (en) 2005-06-10 2011-10-19 Ares Trading S.A. Process for the purification of il-18 binding protein
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
JP6820743B2 (ja) * 2013-09-05 2021-01-27 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）
KR102511343B1 (ko) * 2015-03-05 2023-03-17 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) 및 항체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873453A (ja) * 1994-09-02 1996-03-19 Otsuka Pharmaceut Co Ltd サイトカイン阻害剤
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE69925581T2 (de) * 1998-03-09 2006-04-27 Vertex Pharmaceuticals Inc., Cambridge 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
ME00554B (me) * 2000-05-05 2012-03-20 Serono Lab KORIŠĆENJE IL-18 INHIBITORA ZA LIJEČENJE l/ILI PREVENCIJU ATEROSKLEROZE
EP1292288B1 (en) * 2000-06-23 2004-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US6671553B1 (en) * 2001-05-23 2003-12-30 Pacesetter, Inc. Implantable cardiac lead having terminating connector strain relief and method of manufacture

Also Published As

Publication number Publication date
BG108451A (en) 2005-02-28
JP2004534777A (ja) 2004-11-18
CN1305529C (zh) 2007-03-21
PL216228B1 (pl) 2014-03-31
JP4344142B2 (ja) 2009-10-14
EE200300582A (et) 2004-02-16
US20040191247A1 (en) 2004-09-30
HU230294B1 (hu) 2015-12-28
PT1390070T (pt) 2017-03-01
BG66395B1 (bg) 2013-12-31
ME00550B (me) 2011-10-10
HUP0304067A2 (hu) 2004-03-29
CY1119190T1 (el) 2018-02-14
CA2445664C (en) 2012-03-06
ES2617084T3 (es) 2017-06-15
ZA200308172B (en) 2004-10-21
EE05263B1 (et) 2010-02-15
HRP20030842B1 (hr) 2017-06-02
NO331882B1 (no) 2012-04-23
YU89403A (sh) 2006-05-25
MXPA03010743A (es) 2004-03-02
SK288413B6 (sk) 2016-10-03
CZ20033268A3 (en) 2004-07-14
AU2002314103B8 (en) 2002-12-09
PL367545A1 (en) 2005-02-21
EP1390070A1 (en) 2004-02-25
UA80396C2 (en) 2007-09-25
IL159014A (en) 2012-05-31
RS56006B1 (sr) 2017-09-29
NO20035160D0 (no) 2003-11-20
AU2002314103B2 (en) 2007-07-12
NO20035160L (no) 2003-11-20
SK16032003A3 (sk) 2004-05-04
EP1390070B1 (en) 2017-02-08
CZ307321B6 (cs) 2018-06-06
EA006744B1 (ru) 2006-04-28
HUP0304067A3 (en) 2006-01-30
HRP20030842A2 (en) 2005-08-31
LT1390070T (lt) 2017-03-10
US7655616B2 (en) 2010-02-02
IL159014A0 (en) 2004-05-12
WO2002096456A1 (en) 2002-12-05
KR20040030625A (ko) 2004-04-09
CN1535160A (zh) 2004-10-06
DK1390070T3 (en) 2017-04-24
HK1069762A1 (en) 2005-06-03
CA2445664A1 (en) 2002-12-05
BR0210007A (pt) 2004-08-10

Similar Documents

Publication Publication Date Title
CY1119190T1 (el) Χρηση αναστολεων της il-18 για αγωγη ή προληψη βλαβων του κνς
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
TR200200204T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
BR9812357A (pt) Tratamento de distúbio oposicional desafiador
EP1596854A4 (en) TREATMENT OF DISEASES RELATED TO REDUCED STICK OXIDE BIOVERABILITY, INCLUDING INCREASED ARGINASE
EA200201175A1 (ru) Применение ингибиторов il-18 для лечения и/или предотвращения атеросклероза
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
CY1116137T1 (el) Χρηση των αναστολεων il-18 σε διαταραχες υπερευαισθησιας
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.
FI20011560A0 (fi) Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
UA85187C2 (en) 2-aminobenzoyl derivatives
NO20033634D0 (no) GLYT-1 inhibitorer
EA200500865A1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина
WO2005065693A3 (en) Use of cathepsin z inhibitors for the treatment of rheumatoid arthritis and other autoimmune diseases

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM